CTRI/2022/01/039082进行中（未招募）未知
A multicenter, open label, randomized, balanced, two-treatment, two-period, two-sequence, single dose, cross-over bioequivalence study of Doxorubicin hydrochloride liposome injection 2mg per mL (50 mg per m2 dose) of Sun Pharmaceutical Industries Ltd., India with that of DOXIL® (Doxorubicin hydrochloride liposome injection) 2mg per mL (50 mg per m2 dose) of Janssen Pharmaceutical, Tokyo, Japan in patients with platinum resistant recurrence or relapse mullerian carcinoma (epithelial ovarian cancer, primary fallopian tube cancer, peritoneal cancer) under fed (standardized light meal) condition
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Patient willing and able to provide voluntary informed consent prior to commencement of any study-related activities and the ability to follow the protocol requirements
- •2. Female patients between 18 and 75 years of age, both inclusive and having body mass index greater or equal to 17.00 calculated as weight in kg/height in m2.
- •3. Patients with histologically confirmed mullerian carcinoma (i.e., epithelial ovarian cancer, primary fallopian tube cancer, peritoneal cancer) which is platinum-resistant, recurrence or in relapse state.
- •4. Patient is able and clinically indicated to receive the recommended minimum of 2 cycles of liposomal doxorubicin HCl.
- •5. Patients having Eastern Cooperative Oncology Group performance status of lesser or equal to 2 at the time of screening
- •6. Life expectancy greater than 6 months based on the clinical evaluation by the investigator at the time of screening.
- •7. Patients with acceptable hematology status
- •a) Hemoglobin greater or equal to 9.0 g/dL
- •b) Absolute neutrophil count (ANC) greater or equal to 1500 cells/μL
- •c) Platelet count greater or equal to 75,000 cells/μL
- •d) White blood cell counts (/ mm 3): 3,000 or more and less than 10,000
- •8. Acceptable liver function:
- •a) Alanine aminotransferase (ALT) lesser or equal to 2.5 X ULN
- •b) Aspartate aminotransferase (AST) lesser or equal to 2.5 X ULN
- •c) Total Bilirubin less than 1.2 mg/dL
- •d) Alkaline phosphatase lesser or equal to 3.0 X ULN (lesser or equal to 5 Ã? ULN for bone metastasis)
- •9. Patients with creatinine clearance greater or equal to 60 mL perminute
- •10. Patients with left ventricular ejection fraction greater or equal to 50 percent by an echocardiogram during screening.
- •11. Patients with a negative serum pregnancy test at screening and negative urine pregnancy test on Day 0 (only for females with child bearing potential)
- •12. Women of childbearing potential, (defined as women physiologically capable of becoming pregnant, unless, they must agree to use an effective method of contraception during dosing and up to six months after the last dose of study drug of the investigational product) practicing acceptable method of contraception.
- •Acceptable methods of contraception are:
- •a) Intrauterine device or intrauterine system
- •b) A double barrier method of contraception (Condom and occlusive cap or condom
- •and spermicidal agent)
- •c) Male sterilization (at least 6 months prior to the screening, should be the sole
- •male partner for that patient)
- •d) Female sterilization (surgical bilateral oophorectomy) or tubal ligation or
- •hysterectomy for at least 6 weeks or post-menopausal for at least one-year prior
- •to study participation
- •e) Total abstinence, partial abstinence is not acceptable.
- •13. Patients with no history of addiction to any recreational drug or drug dependence or alcohol addiction
排除标准
- •1. Patients with known hypersensitivity or contraindication including anaphylaxis to conventional or liposomal formulations of doxorubicin, anthracycline therapy, peanut or soya or to any of their components
- •2. Patients with prior doxorubicin exposure that would result in a total lifetime exposure of more than 450 mg/m2 (prior use of other anthracyclines or anthracenodiones should be included in calculations of total cumulative dosage)
- •3. Patients who have received previous chemotherapy and radiation therapy within 4 weeks of dosing of Investigational Product
- •4. Patients with impaired cardiac function including any of the following conditions within 6 months prior to screening:
- •a. Unstable angina
- •b. QTc prolongation or other significant ECG abnormalities.
- •c. Coronary artery bypass graft surgery.
- •d. Symptomatic peripheral vascular disease.
- •e. Myocardial infarction
- •f. NYHA class II-IV heart failure
- •g. Severe uncontrolled ventricular arrhythmias
- •h. Clinically significant pericardial disease
- •i. Electrocardiographic evidence of acute ischemic or active conduction system
- •abnormalities
- •5. Patients who have received any prior mediastinal irradiation as cardiac toxicity may occur at even lower doses (400mg/m2)
- •6. Patients who have received trastuzumab within 24 weeks prior to dosing of investigational product and who require as part of treatment during the study
- •7. Patients taking inducers and inhibitors of CYP3A4, CYP2D6 or P-gp
- •8. Pregnant or lactating women
- •9. Patients with uncontrolled metabolic disorders including diabetes mellitus (HbA1c >= 9 %) at screening
- •10. Patients with active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, Pneumocystis carinii, or other microorganism if under treatment with myelotoxic drugs
- •11. Patients with known central nervous system metastasis
- •12. Patients with major surgical procedure (including periodontal) within 28 days of the first dose of Investigational Product
- •13. Patients with surgical or other non-healing wounds
- •14. Patients with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), syphilis.
- •15. Patients with history of other malignancies in the last 5 years (except in situ cancer or basal or squamous cell skin cancer)
- •16. Patients who have not recovered to Grade 0 or 1 toxicities from previous anticancer treatments or previous investigational agents. Exceptions are alopecia (any grade is acceptable), Hemoglobin greater or equal to 9.0 g/dL and fatigue (Grade 2 is acceptable) {Per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], V5.0}.
- •17. Patients with any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the patient to participate in the study including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requirements.
- •18. Patients who have participated in any clinical study within 90 days before the first dose of Investigational Product
- •19. Patient who have donated blood and/or loss of greater or equal to 350 mL (1 unit) of blood within 90 days before the first dose of Investigation
研究者
相似试验
招募中
不适用
multicenter, open label, three periods, three sequence single dose bioequivalence study of Doxorubicin Injection in female patients with ovarian cancerCTRI/2021/03/032185ForDoz Pharma Corp
已完成
不适用
A multicenter, open label, randomized, balanced, two treatment, two period, twosequence, crossover, single dose, bioequivalence study of Docetaxel in patients with solid tumoursCTRI/2021/04/033049Zhuhai Beihai Biotech Co Ltd46
尚未招募
不适用
A multicenter, open label, randomized, balanced, two-treatment, single-period, multiple dose, parallel study to compare efficacy of Tiotropium Bromide inhalatioCTRI/2018/08/015399Dongguan HEC Pharm RD Co Ltd
尚未招募
不适用
This is a comperative study of Capecitabine Capsule 500 mg tablets manufactured by sponsor with Xeloda 500 mg Tablets of Genetech USA, A Member of Roche group, USA, in adult patients with Breast cancer and Colorectal cancer under fed condition.CTRI/2012/04/002607Amneal Pharmaceuticals Ltd57
已完成
不适用
Bioequivalence study of Doxorubicin Hydrochloride Liposome Inj(20mg/10mL) administered in female patients with ovarian cancer.CTRI/2018/04/013185Mylan Laboratories Limited125